Amphetamine

Amphetamine

SCHEMBL113682

CC(N)Cc1ccccc1.O=P(O)(O)O

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3

The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 3/20 0.76
SLC6A3 known ✓ Q01959 1/20 0.76
TAAR1 Q96RJ0 5/20 0.76
SLC6A4 P31645 3/20 0.76
MAOA P21397 1/20 0.76
SIGMAR1 Q99720 1/20 0.76
CYP2A6 P11509 1/20 0.76
ADORA2A P29274 1/20 0.76
ADORA1 P30542 1/20 0.76
LAP3 P28838 5/20 0.63
ANPEP P15144 2/20 0.63
CYP2D6 P10635 1/20 0.53
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dextroamphetamine SCHEMBL547496 1.00 TAAR1 (0.76) TAAR1SLC6A2SLC6A4MAOASLC6A3
Levamfetamine SCHEMBL31637605 0.94 TAAR1 (0.73) TAAR1SLC6A2SLC6A4MAOASLC6A3
Amphetamine SCHEMBL16858761 0.94 TAAR1 (0.73) TAAR1SLC6A2SLC6A4MAOASLC6A3
Dextroamphetamine SCHEMBL17924971 0.94 TAAR1 (0.73) TAAR1SLC6A2SLC6A4MAOASLC6A3
Amphetamine SCHEMBL10600513 0.90 TAAR1 (0.61) TAAR1SLC6A2SLC6A4MAOASLC6A3
Amphetamine SCHEMBL4382899 0.89 LAP3 (0.66) TAAR1SLC6A2SLC6A4MAOASLC6A3
Amphetamine SCHEMBL28990193 0.87 TAAR1 (0.91) TAAR1SLC6A2SLC6A4MAOASLC6A3
Amphetamine SCHEMBL13747801 0.87 SLC6A2 (1.00) TAAR1SLC6A2SLC6A4MAOASLC6A3
Dextroamphetamine SCHEMBL8859 0.87 SLC6A2 (1.00) TAAR1SLC6A2SLC6A4MAOASLC6A3
Amphetamine SCHEMBL1560962 0.87 SLC6A2 (1.00) TAAR1SLC6A2SLC6A4MAOASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2318 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026086030-A1 METHOD FOR CONSTRUCTING CHIRALITY OF PYRAN RING IN ORFORGLIPRON BY MEANS OF ENZYMATIC CATALYSIS 成都安迈博生物医药有限公司 2026-04-30 WO claimed
US-12570539-B2 Systems and methods for generating radionuclides PERSPECTIVE THERAPEUTICS, INC. (US) 2026-03-10 US claimed
US-20260008686-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES PERSPECTIVE THERAPEUTICS INC (US) 2026-01-08 US claimed
US-20250388564-A1 METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS EDGEWISE THERAPEUTICS INC (US) 2025-12-25 US claimed
US-20250368525-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES PERSPECTIVE THERAPEUTICS INC (US) 2025-12-04 US claimed
US-20250372274-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES PERSPECTIVE THERAPEUTICS INC (US) 2025-12-04 US claimed
US-20250270230-A1 NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL BOEHRINGER INGELHEIM INT (DE) 2025-08-28 US claimed
WO-2025131986-A1 NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-06-26 WO claimed
EP-4568984-A1 PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE F. Hoffmann-La Roche AG (CH) 2025-06-18 EP claimed
EP-4568784-A2 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES Perspective Therapeutics, Inc. (US) 2025-06-18 EP claimed
US-20030194439-A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate MIDHA KAMAL K (BM) 2003-10-16 US claimed
US-6555136-B2 First, second and optionally third dosage units, with each dosage unit having a different drug release profile. PHARMAQUEST, LTD. (BM) 2003-04-29 US claimed
WO-2002059089-A2 PROCESS FOR THE PREPARATION OF HETEROCYCLIC INDENE ANALOGS F. HOFFMANN-LA ROCHE AG (CH) 2002-08-01 WO claimed
US-20020058061-A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate MIDHA KAMAL K (CA) 2002-05-16 US claimed
EP-1191924-A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF (D-THREO)-METHYLPHENIDATE AND A SECOND CNS STIMULANT Pharmaquest Limited (BM) 2002-04-03 EP claimed
EP-1165054-A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE Pharmaquest Limited (BM) 2002-01-02 EP claimed
US-6217904-B1 MIXTURES; ADMINISTERING IN CYCLES PHARMAQUEST LTD. (BM) 2001-04-17 US claimed
WO-2000059481-A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT PHARMAQUEST LTD. (BM) 2000-10-12 WO claimed
WO-2000059479-A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE PHARMAQUEST LTD. (BM) 2000-10-12 WO claimed
EP-0355825-A2 Viral treatment system Prendergast, Patrick T. (IE) 1990-02-28 EP claimed